Kornimate/medical-research-clean huggingface dataset:
comparison of standard and endoscope assisted endotracheal intubation

Conditions: Biliary Tract Diseases; Pancreatic Diseases

Summary: comparison of standard endotracheal intubation and endoscopist-facilitated endotracheal intubation

endoscopic retrograde cholangiopancreatography (ercp) procedures are typically performed using general anesthesia. during anesthesia, the anesthesiologist inserts a breathing tube (endotracheal tube) into the patient's wind pipe (trachea) and a machine helps the patient breathe (mechanical ventilation) while they are unconscious. the breathing tube is inserted with a patient laying on his/her back using a rigid metallic device (laryngoscope) to guide tube placement. the unconscious patient is then moved from the portable bed onto the x-ray table by nursing staff. the patient also has to be turned to lie on their stomach on the x-ray table for the procedure. this standard approach carries a small risk of patient injury during breathing tube placement as well as while moving and turning the unconscious patient onto the x-ray table. at our endoscopy unit, endoscopists have, on several occasions, used a slim gastroscope to place the breathing tube under direct visualization in patients who are already positioned on their stomach for ercp. this approach is rapid and has been uniformly successful and safe. we hypothesize that this endoscopist-facilitated intubation approach may expedite the procedure and minimize ergonomic strain for staff during patient repositioning while minimizing patient injury during breathing tube placement and repositioning. this study seeks to formally compares the two approaches for placement of a breathing tube.

Eligibility criteria:
inclusion criteria: * patients undergoing ercp at stanford university medical center exclusion criteria: * unable to consent * contra-indication to general anesthesia

Keywords: ercp endoscopic procedures anesthesia
postmarketing surveillance study to assess handling and patient satisfaction on berodual® respimat® solution for inhalation in patients with chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: new perceptions about handling and patient satisfaction of the everyday use of berodual® respimat® in patients with chronic obstructive lung disease (cold). moreover, further knowledge should be attained about the tolerability of berodual® respimat®


Eligibility criteria:
inclusion criteria: * male and female patients aged at least 18 years who were suffering from symptoms of a cold (naive or pre-treated) could be included in the pms exclusion criteria: * patients who meet one or more of the general or specific contraindications mentioned in the summary of product characteristics (smpc) are excluded from the postmarketing surveillance (pms)
prospective study of the impact of insulin pump therapy in young children with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of the study is to examine glycemic and neuropsychological outcomes in very young children with type i diabetes who are being started on insulin pumps and to compare their outcomes to children who are not utilizing insulin pumps. we propose to assess 40 children with iddm under 5 years of age. 10 patients examined will be using multiple daily injections with basal glargine, 10 will be using nph or lente and rapid-acting insulin, and 20 will be examined prior to and 12 months after the implementation of insulin pump therapy. these subjects will be recruited and followed because they are currently undergoing treatment for type 1 diabetes. children will be recruited based upon the insulin regimen that they and their primary diabetes physician have chosen to utilize clinically. insulin regimens will not be changed by the study team. outcome measures will examine: glycemic outcomes (overall control, blood sugar variability), cognitive outcomes, parenting stress, and changes in diet.


Eligibility criteria:
inclusion criteria: 1. children with type i diabetes: 2. children must be 5 years of age or less at the time of entry into the study. 3. children must have had a diagnosis of type i diabetes for at least 1 year at time of entry. 4. children must be receiving two or more insulin injections daily. exclusion criteria: 1. children will be excluded if they have additional medical problems requiring treatment with agents known to affect blood glucose such as steroids or l-asparaginase. 2. children must not have any other chronic illness in addition to diabetes.

Keywords: type 1 diabetes continuous glucose sensor monitoring
effects of a prehabilitation program in patients undergoing lumbar radiculopathy surgery

Conditions: Lumbar Radiculopathy

Summary: the purpose of the following study is to analyze the effects of a prehabilitation program based on therapeutic exercise, back care education and pain neuroscience education through the visualization of videos, compared to standardized written therapeutic exercise in patients undergoing lumbar radiculopathy surgery.

so far, there are no previous studies that analyze the effects of a prehabilitation program including therapeutic exercise, back care education and pain neuroscience education through the visualization of videos in patients undergoing lumbar radiculopathy surgery. this is a multicenter randomized clinical trial aimed at analyzing the effects of a 4 weeks prehabilitation program based on video visualization versus the performance of standardized written exercises in patients undergoing lumbar radiculopathy surgery.

Eligibility criteria:
inclusion criteria: * adults aged 18 years or older, diagnosed with lumbar radiculopathy, and scheduled for surgery. the symptoms will be predominantly leg pain with or without neurological deficit, with surgical decompression justified. exclusion criteria: * patients currently receiving any other non-pharmacological treatment or physical therapy for the management of lumbar radiculopathy. * proposed for surgery with instrumentation (e.g., spinal fusion, arthrodesis). * suffering from a chronic pain-related condition (e.g., fibromyalgia, chronic fatigue syndrome). * symptoms of spinal cord compression. * diagnosed with a malignant tumor. * mental illness. * previously undergone spinal surgery. * no access to any internet-enabled device.
a low-resource oxygen blender prototype for use in modified bubble cpap circuits

Conditions: Respiratory Distress Syndrome; Lower Respiratory Tract Infection

Summary: purpose: using a novel oxygen blender prototype with modified bcpap to manage children 1 month to 5 years of age hospitalized with respiratory distress due to lower respiratory tract infection (lrti) in low-resource settings is not associated with clinical failure within 1 hour of use. aim: to investigate if this novel oxygen blender is safe to use among children 1 month to 5 years old hospitalized for respiratory distress from lower respiratory tract infections in a low-resource setting.

the study will be a prospective cohort feasibility and safety trial. patients admitted to chenla children's healthcare who meet eligibility criteria will be asked for consent and then enrolled. once enrolled, the participant will be treated per hospital protocols and stabilized on bcpap respiratory support. once stable for 2 hours, the blender will be incorporated into the bcpap circuit. at this point, the study nurses will begin recording data for the study as well as providing standard medical care per hospital protocols.

Eligibility criteria:
inclusion criteria: * admitted for lung disease and require hospitalization * admission diagnosis is lower respiratory tract infection or pneumonia or bronchiolitis (any infectious microbe including bacterial, viral, fungal, parasitic) * have respiratory distress on presentation to the hospital (cough or trouble breathing plus at least one of the following: \<92% despite low flow oxygen, central cyanosis, tachypnea, chest indrawing, nasal flaring, grunting, head nodding, convulsions, lethargy, inability to breastfeed or drink) * a bcpap (electronic) machine is not available to use exclusion criteria: * history of asthma * upper airway obstruction * diaphragmatic hernia * pneumothorax * acute glasgow coma score \<4 * cleft palate * cyanotic heart disease * bleeding disorders * imminent death within 2 hours * have had abdominal or thoracic surgery
rad001 in combination with capecitabine and oxaliplatin (xelox) in patients with advanced gastric cancer: rad001+xelox

Conditions: Advanced Gastric Cancer

Summary: it is expected that rad001 works in gastric cancer by inhibiting pi3k/akt/mtor pathway and hif1a (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the growth of tumors like renal cell carcinoma.however, rad001 alone looks not enough to control gastric cancer. by the mechanisms above, rad001 can show additive or synergistic effect in combination with conventional chemotherapy. in this study, xelox was selected as a conventional combination chemotherapy because it was proven very active and safe in gastric cancer. combination of xelox and rad001 has been never tried for the treatment of cancer patients yet. so, the optimal dose will be first determined in this phase i study

for the first cohort of this phase i study, each drug of capecitabine, oxaliplatin, and rad001 will be started at one or two dose below the ordinary full dose of each drug as a single agent.

Eligibility criteria:
inclusion criteria: * histologically or cytologically documented unresectable or metastatic adenocarcinoma of stomach or gastroesophageal junction * no history of chemotherapy or radiation * age 18 to 70 years old * estimated life expectancy of at least 3 months * eastern cooperative oncology group (ecog) performance status 0-2 * adequate bone marrow function (white blood cell counts \>3,000/ul, absolute neutrophil count\>1,500/ul, platelets\>100,000/ul, hgb\>8 g/dl) * adequate kidney function (creatinine\<1.5 mg/dl) * adequate liver function (bilirubin\<1.5 mg/dl, aspartate aminotransferase (ast) or alanine aminotransferase (alt) level \<3 times the upper normal limit (5 times for patients with liver metastasis)) * signed written informed consent exclusion criteria: * past or concurrent history of neoplasm other than gastric adenocarcinoma except for curatively treated basal cell carcinoma of skin or in situ carcinoma of the cervix uteri * major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start * presence of central nervous system metastasis * bowel obstruction * evidence of serious gastrointestinal bleeding * peripheral neuropathy (nci ctc ae version 3.0 \> grade i) * history of significant neurologic or psychiatric disorders * pregnant or lactating women, women of childbearing potential not employing adequate contraception * other serious illness or medical conditions * patients with known history of ischemic heart disease and/or with myocardial infarction * known allergy to study drugs * administration of drugs showing interaction with rad001

Keywords: xelox rad001 phase 1
complications of mesh procedures for stress urinary incontinence

Conditions: Urinary Incontinence; Stress

Summary: complications from mesh procedures (i.e. insertion of tension-free vaginal tapes (tvt), trans-obturator tapes (tot) and suprapubic slings (ss)) used during surgical treatment of stress urinary incontinence have caused major concern around the world. the investigators aim to conduct a retrospective cohort study using administrative inpatient data from the hospital episode statistics (hes) database to determine the complications of all first-time surgical mesh procedures in the treatment of stress urinary incontinence (sui) in women treated in a national health service (nhs) hospital in england who were discharged from hospital between 1st april 2007 and 31st march 2015. the primary outcome measure is the number and types of complications (occurring peri-procedurally, within 30 days of the mesh procedure and those occurring during follow-up). additional outcomes recorded include: the numbers and types of mesh procedures, including those with potentially confounding concomitant procedures.


Eligibility criteria:
inclusion criteria: * women with an office of population censuses and surveys classification of surgical operations and procedures 4th revision (opcs-4) procedure code for an introduction of a tension-free vaginal tape (tvt: m53.3), trans-obturator tape (tot: m53.6) or supra-pubic sling (ss: m52.1) surgical mesh procedure recorded in any of the 24 procedure fields captured in hes, and a recorded diagnosis of stress urinary incontinence based on international classification of diseases 10th revision (icd-10) diagnoses: n39.3, n39.4, r32: t83.1, t83.4, t83.5, t83.6, t83.6, t83.8, t83.9, z46.6, in any of the 20 diagnosis fields captured in hes. exclusion criteria: * duplicate episode of care (exact match on patient identifier; admission date and method; discharge date, destination and method; hospital, gender, age, all procedure codes and all diagnostic codes) * male gender * missing age * aged less than 18 years * invalid or missing admission method * missing admission date * patients with recorded episodes of care in hes which appear after a reported date of death. * concomitant mesh surgery for pelvic organ prolapse surgery, or surgical mesh repair, removal, renewal or subsequent mesh insertion.

Keywords: surgical mesh observational study intraoperative complications postoperative complications
an imaging framework for clinically testing new treatments to prevent post-traumatic oa

Conditions: Orthopedic Disorder; Trauma; Ankle Fractures; Post-traumatic Osteoarthritis

Summary: the immediate goal of the proposed research is to test the value of a new low-cost, low-dose standing ct system for efficient early detection of both joint degeneration and elevated contact stress. the standing ct scanner holds promise for detecting arthritic changes earlier than other imaging modalities because of the combination of its 3d nature and ability to image joints in a weight-bearing pose. a secondary goal of the proposed research is to enable predictive models for osteoarthritis risk based on measures of post treatment contact stress, both to inform treatment and so that new interventions can be tested in a manner incorporating risk stratification.

individuals who present with an intra-articular of the tibial plafond will be consented to participate in this study. we will obtain pedcat scans at 6, 12, and 18 months post-injury, as well as several questionnaires that will be administered during the clinical visits. we will also review the subjects' electronic medical record for data related to the injury, including the timing and mechanism of injury, time from injury to surgery, length of hospital stay, any complications and/or subsequent ankle surgeries, as well as any clinic notes, imaging, and/or outcomes scores related to the calcaneus fracture.

Eligibility criteria:
inclusion criteria: * individuals 18 to 70 years old sustained an intra-articular fracture of the tibial plafond indicated for operative treatment present for treatment within 4 weeks of injury exclusion criteria: * women who are pregnant or planning on becoming pregnant individuals younger than 18 and older than 70
a study evaluating the safety, tolerability, and efficacy of evo756 in adults with chronic inducible urticaria

Conditions: Chronic Inducible Urticaria

Summary: this phase 2a trial will evaluate the safety and efficacy of evo756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of chronic inducible urticaria for at least 3 months. * positive response following provocation using the temptest or frictest at screening and day 1. exclusion criteria: * history of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema. * concurrent use of certain medications, including antihistamines. * any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.

Keywords: chronic inducible urticaria inducible urticaria
the success of lumbar sympathetic ganglion block using lower extremity perfusion index

Conditions: Chronic Pain; Complex Regional Pain Syndromes; Peripheral Neuropathy; Post Herpetic Neuralgia

Summary: the patient, who is experiencing chronic pain in the lower extremities persisting for more than three months, is scheduled to undergo lumbar sympathetic ganglion block. to evaluate the technical success of the sympathetic blockade, temperature and perfusion index (pi) will be measured at one-minute intervals over a 20-minute period before and after the procedure on the treated side and the opposite side foot. additionally, other variables related to the procedure will be assessed before the procedure, after the procedure, before discharge, and during follow-up outpatient visits or phone surveys at 1 week and 1 month after the procedure.

patients aged 19 to 85 experiencing lower limb pain and scheduled to undergo lumbar sympathetic ganglion block at the seoul national university hospital pain center will be directly informed about the study, and their participation will be sought and registered. continuous monitoring of electrocardiography, blood pressure, and pulse oximetry will be conducted before and after the procedure. upon admission to the pain center's operating room, the patient will assume a prone position. thermometers will be attached to the soles of both feet, and perfusion index probes will be attached to the second toe on both sides. using fluoroscopy guidance, a needle will be inserted at the painful side, either right or left, at the l3. after confirming the needle's position in front of the desired vertebral body using contrast medium in lateral and anteroposterior (ap) views, 7 ml of 0.5% ropivacaine will be injected. baseline temperature and pi values will be recorded before drug administration, followed by recording every minute for 20 minutes after injection. other variables related to the procedure will be assessed before and after the procedure, before discharge, and through outpatient visits or phone surveys at one week after the procedure.

Eligibility criteria:
inclusion criteria: * lower extremity pain * pain for more than 3 months * 19 - 85 years exclusion criteria: * if the patient refuses to undergo the procedure * in the presence of vascular disorders in the lower extremities * if the patient has previously undergone lumbar sympathetic ganglion removal or neurolysis * when there are abnormalities in blood coagulation tests * if there is a systemic infection or infection at the injection site * in the presence of anatomical deformities at the injection site * if the patient has allergies to the injected medication * in other cases where the researcher deems the patient unsuitable for participation
neoadjuvant cetuximab + chemotherapy combined with short-course radiotherapy

Conditions: Neoadjuvant Treatment; Rectal Cancer; Cetuximab; Radiotherapy

Summary: prospectively investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mfolfox6) combined with short-course radiotherapy (25gy/5fx) for ras wild-type locally advanced rectal cancer


Eligibility criteria:
inclusion criteria: 1. a biopsy proven histological diagnosis of rectal adenocarcinoma； 2. an arms-pcr proven kras, nras, pi3kca and braf wild type; 3. no intestinal obstruction, distant metastasis was excluded by ct, mri or pet / ct; 4. mri proven t3c-t4, crm positive, n2, extramural vascular invasion positive or lateral lymph node positive of locally advanced rectal cancer; 5. age between 18-75 years; 6. ecog (eastern us cooperative oncology group) score: 0-1; 7. has sufficient organ function: * hemopoietic function: hemoglobin ≥ 90 g / l, platelet ≥ 80 g / l × 109 / l, neutrophils ≥ 1.5 × 109/l * liver function: alt and ast \< 2.5 × uln; * renal function: serum creatinine \< 1.5 uln; 8. willing to participate and informed consent signed； exclusion criteria: 1. patients with mutations in any of kras, nras, or braf, microsatellite instablility-high; 2. patients having undergone chemotherapy, radiotherapy or surgery for colorectal cancer; 3. patients with other uncontrolled malignant tumors (except early-stage basal cell carcinoma or cervical carcinoma in situ) ; 4. female patients who are pregnant or breastfeeding; 5. patients with severe heart, liver, or kidney, or neurological or psychiatric disease; 6. patients with active infection; 7. poor overall health status, ecog ≥ 2; 8. patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study in the judgment of the investigator; 9. known hypersensitivity reactions to any investigational drugs;
enteral nutrition as stress ulcer prophylaxis in critically ill patients.

Conditions: Gastrointestinal Hemorrhage; Clostridium Difficile Colitis

Summary: study is to determine if proton pump inhibitors plus enteral nutrition is superior to enteral nutrition alone as a stress ulcer prophylaxis strategy in critically ill patients in terms of incidence of overt and significant gi bleeding related to stress gastropathy.


Eligibility criteria:
inclusion criteria: * age 18 years or older * admission to the medical icu at university of louisville hospital or jewish hospital * expected need for mechanical ventilation \> 48 hours * no contraindication to en within the first 24 hours after admission to the icu exclusion criteria: * evidence of active gi bleeding during current hospitalization prior to study entry * admission to icu with primary diagnosis of burn injury * closed head injury or increased intracranial pressure * partial or complete gastrectomy * pregnancy or lactation

Keywords: enteral nutrition stress ulcer prophylaxis critically ill patients overt and significant gi bleeding stress gastropathy clostridium difficile pseudomembranous colitis vital af small peptide fish oil structured lipids fructose oligosaccharide
a study to learn about how medicines called cdk4/6 inhibitors are used in people with advanced or metastatic breast cancer in australia

Conditions: Breast Neoplasms

Summary: the purpose of this study is to learn about how a class of medicines called cdk4/6 inhibitors, are used for the treatment of breast cancer in patients in australia. the study looks at how the cdk4/6 inhibitor class of drugs are used for treating breast cancer that is advanced or metastatic (has spread to other parts of the body). this study does not include patients. instead, this study looks at already available data to describe characteristics (like age and sex) of patients who have already taken these medicines. this study will focus on one of these medicines called palbociclib and will look at the data to learn what amounts of the study medicine (palbociclib) patients receive, and how long patients take it for in the real-world in australia. this study will also learn what other anti-cancer medicines patients receive, including chemotherapy. chemotherapy is the treatment that uses medicines to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.


Eligibility criteria:
inclusion criteria: * 18 years or older when first received cdk4/6i breast cancer treatment * patient who has received cdk4/6i during study period exclusion criteria: * there are no exclusion criteria for this study

Keywords: breast cancer metastatic breast cancer